Research programme: biologics substitution therapeutics- Rapafusyn Pharmaceuticals
Latest Information Update: 13 May 2025
At a glance
- Originator Rapafusyn Pharmaceuticals
- Class Anti-inflammatories; Cyclic peptides; Macrocyclic compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders; Inflammation
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 29 Apr 2025 Research programme: Biologics substitution Therapeutics- Rapafusyn Pharmaceuticals is available for licensing as of 29 Apr 2025. https://rapafusyn.com/
- 29 Apr 2025 Early research in Autoimmune disorders in USA (unspecified route) prior to April 2025 (Rapafusyn Pharmaceuticals pipeline, April 2025)
- 29 Apr 2025 Early research in Inflammation in USA (unspecified route) prior to April 2025 (Rapafusyn Pharmaceuticals pipeline, April 2025)